1 completed, 1 recruiting, 1 suspended, 1 terminated. 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Recruiting 1, Suspended 1, Terminated 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Communicable Diseases, Emerging: new trials by email Literature Review of Communicable Diseases, Emerging trials Research Report on Communicable Diseases, Emerging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARN-75039 Lassa Fever Treatment in West Africa ARN-75039 high, Intravenous ribavirin, ARN-75039 low - Lassa Fever | Phase 2 | Suspended | Arisan Therapeutics, Inc. | 135 | 2026-02-14 | 2026-07-06 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Favipiravir, Ribavirin, Dexamethasone - Lassa Fever | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | 1755 | 2025-05-02 | 2026-02-04 |
| EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial Baricitinib, Placebo - COVID-19, Emerging Infectious Disease | Phase 2 / Phase 3 | Terminated | Oslo University Hospital | 290 | 2021-06-03 | 2023-02-06 |
| Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza Anti-Influenza Immune Plasma, Standard Care - Influenza A, Influenza B | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 98 | 2010-12-01 | 2017-09-05 |
Hemorrhagic Fevers, Viral (2) · Lassa Fever (2) · COVID-19 (1) · Neglected Diseases (1) · Orthomyxoviridae Infections (1)
Communicable Diseases (4) · Disease Attributes (4) · Infections (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · RNA Virus Infections (4) · Virus Diseases (4) · Arenaviridae Infections (2) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · Respiratory Tract Diseases (1)
Standard of Care (2) · Dexamethasone (1) · Ribavirin (1) · baricitinib (1) · favipiravir (1)
Arisan Therapeutics, Inc. (1) · Irrua Specialist Teaching Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oslo University Hospital (1)
Nigeria (2) · United States (2) · Austria (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Ireland (1) · Italy (1) · Liberia (1) · Luxembourg (1) · Norway (1) · Portugal (1)
Domique Costagliola, PhD (1) · John Beigel, MD (1) · Jose R Arribas, MD PhD (1) · Ken McCormack, PhD (1) · Richard Davey, MD (1)